Pfizer’s CTI for NIH has two calls for proposals each year. The spring 2018 call for proposals opened on March 12, 2018. Pre-proposals are due by April 23, 2018. Learn more about the therapeutic areas of interest for the spring 2018 cycle.
Advantages to Collaborating with CTI
A cooperative research and development agreement (CRADA) collaboration with CTI includes, among other things, access to Pfizer’s drug development expertise and publishing rights. CTI’s foundation partners include:
- Lupus Research Alliance
- Alzheimer’s Drug Discovery Foundation
- Crohn’s and Colitis Foundation of America
- Juvenile Diabetes Research Foundation
- Jeffrey Modell Foundation
See the therapeutic areas of interest.
- As a general rule, CTI does not accept therapeutics of the following kinds: small molecule, radiotherapy, nanoparticle delivery systems and vaccines.
- Pre-proposals for collaboration will be evaluated initially on the basis of fit with Pfizer internal program portfolios, other CTI collaborations, and business and technical feasibility specific to each project.
- RNAi, CRISPR technologies and nanoparticles are not in the scope for the current CTI call for proposals.
Success Factors: What We Look For
- Strong project rationale
- Demonstrated association between target biology pathway and disease mechanism
- Target validation as demonstrated by genetic or pharmacologic evidence
- Ability to address unmet medical needs
- Validated therapeutic drug target
- Tractable target relative to proposed drug modalities (antibodies, proteins and peptides)
- Novel target, novel therapeutic strategy or new insight into target patient population
- Defined target
- Understanding of desired pharmacology
- Demonstrated cause-effect relationship to disease mechanism
- Project feasibility
- Clear path to candidate development (biochemical/cell-free/cellular assays, disease models, pre-clinical testing, etc.)
- Clear path for translation into clinical trials (approach for proof-of-mechanism in humans, accessible patient population, time frame, safety issues, etc.)
- Clinical differentiation
- Therapeutic strategies including personalized medicine, patient stratification, molecular signatures, genetic associations and biomarkers
- Large molecules (antibodies, proteins, antibody conjugates and fusion proteins)
Proposal Submission Process
All intramural NIH researchers and clinicians whose work meets these criteria are invited to apply to CTI. The first step is submitting a pre-proposal brief (Word - 39KB), which is a non-confidential two- to three-page overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic drug. At a high level, the pre-proposal should explain how the therapeutic hypothesis could be tested in the clinic. Investigators then must submit this pre-proposal to their NIH Institute or Center's technology transfer office for initial review and for submission to the Pfizer CTI Portal. For more information, contact Nader Halim, Ph.D., or Lili Portilla, M.P.A.
The NIH-Pfizer Joint Steering Committee reviews all submitted proposals. Responses to pre-proposals will be provided mid-May 2018. For selected projects, a team of scientists from CTI and NIH will work together to submit a full proposal and project plan to advance the research.
- Stage I: Pre-proposal submission and non-confidential review
- Stage II: Full proposal submission and confidential review
- Stage III: Work plan and budget